MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Hold” by Analysts

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have received an average rating of “Hold” from the sixteen research firms that are currently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $27.8462.

MLTX has been the topic of a number of research reports. Needham & Company LLC lifted their price objective on MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. BTIG Research increased their target price on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. The Goldman Sachs Group lowered shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and raised their target price for the company from $8.00 to $10.00 in a report on Wednesday, January 14th. Oppenheimer boosted their price target on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. Finally, Royal Bank Of Canada upped their price target on shares of MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the company a “sector perform” rating in a research note on Monday, March 2nd.

MoonLake Immunotherapeutics Trading Up 0.2%

Shares of MoonLake Immunotherapeutics stock opened at $16.77 on Friday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -4.76 and a beta of 1.20. The business has a 50-day moving average price of $16.74 and a 200-day moving average price of $19.71. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. MoonLake Immunotherapeutics has a twelve month low of $5.95 and a twelve month high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.92). During the same period in the prior year, the firm earned ($0.72) earnings per share. Equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Institutional Trading of MoonLake Immunotherapeutics

Hedge funds have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in MoonLake Immunotherapeutics in the fourth quarter worth about $166,000. T. Rowe Price Investment Management Inc. bought a new stake in MoonLake Immunotherapeutics during the fourth quarter worth approximately $47,000. Vident Advisory LLC purchased a new stake in MoonLake Immunotherapeutics during the fourth quarter valued at approximately $204,000. Virtus Investment Advisers LLC lifted its stake in shares of MoonLake Immunotherapeutics by 595.8% in the 4th quarter. Virtus Investment Advisers LLC now owns 17,987 shares of the company’s stock valued at $237,000 after purchasing an additional 15,402 shares during the last quarter. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter valued at approximately $3,347,000. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.